Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings
Latest Information Update: 25 Oct 2021
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Acronyms Correlate
- Sponsors Bayer
- 25 Oct 2021 Results (n=128) of an analysis assessing safety and effectiveness of regorafenib in Taiwanese subpopulation from this trial published in the Journal of the Formosan Medical Association
- 04 Nov 2019 Results (n=1037) assessing safety and effectiveness of in patients with metastatic colorectal cancer published in the European Journal of Cancer
- 19 Jan 2019 Results presented at the 2019 Gastrointestinal Cancers Symposium